secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK:        0001314052
Form:       8-K
Filed at:   2026-08-11T21:00:32+00:00
Accession:  0001731122-26-001042
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anavex files proxy for Sep 24 meeting, adds two independent directors amid PVG proxy fight
--------------------------------------------------------------------------------

- 2026 annual meeting set for Sep 24, 2026; record date Jul 31, 2026; PVG owns 0.35% of shares.
- Board nominates Gautam Patel and Dr. Adrian Senderowicz as new independent directors; half of board refreshed.
- Interim CEO Dr. Terrie Kellmeyer leading; blarcamesine advanced in Alzheimer's, Rett, Fragile X with FDA talks.
- Anavex urges votes for six WHITE card nominees; cites PVG slate lacks FDA/drug development expertise.
- Nasdaq delinquency notice for late Q1 10-Q received May 20, 2026; listing unaffected, compliance plan filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226001042/0001731122-26-001042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226001042/e7842_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-001042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer